Sight Sciences, Inc.
NASDAQ:SGHTMedical - Devices
+$0.15 today
- Market cap
- $590.25M
- Beta
- 2.41
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$0.69
Volume 0.38M
Average 0.25M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Sight Sciences, Inc.
NASDAQ:SGHT
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +2.7% | +11.7% (4yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +2.7% over three years. Forward estimates point to Revenue at +11.7% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alcon Inc. NYSE:ALC | $35.61B | $74.12 | Undervalued | 38.7 | -0.25% |
Glaukos Corporation NYSE:GKOS | $14.55B | $245.72 | Not rated | -39.0 | +150.11% |
Bausch Health Companies Inc. NYSE:BHC | $3.13B | $8.35 | Undervalued | -1.5 | +42.67% |
Ocular Therapeutix, Inc. NASDAQ:OCUL | $1.37B | $6.21 | Not rated | -7.3 | -50.00% |
Harrow Health, Inc. NASDAQ:HROW | $1.13B | $30.12 | Overvalued | -104.7 | -14.68% |
SpyGlass Pharma, Inc. Common Stock NASDAQ:SGP | $1.10B | $32.88 | Not rated | -14.1 | — |
Continue the stock analysis
Jump to another research area for this company.